192 related articles for article (PubMed ID: 25961655)
1. Masitinib for the treatment of mild to moderate Alzheimer's disease.
Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
[TBL] [Abstract][Full Text] [Related]
2. Masitinib for the treatment of Alzheimer's disease.
Ettcheto M; Cano A; Sanchez-López E; Verdaguer E; Folch J; Auladell C; Camins A
Neurodegener Dis Manag; 2021 Aug; 11(4):263-276. PubMed ID: 34412534
[TBL] [Abstract][Full Text] [Related]
3. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
4. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.
Prosvicova J; Lukesova S; Kopecky J; Grim J; Papik Z; Kolarova R; Navratilova B; Dubreuil P; Agopian J; Mansfield C; Moussy A; Hermine O
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):695-7. PubMed ID: 26725706
[TBL] [Abstract][Full Text] [Related]
5. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of masitinib for treating systemic mastocytosis.
Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
[No Abstract] [Full Text] [Related]
7. Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease.
Li T; Martin E; Abada YS; Boucher C; Cès A; Youssef I; Fenaux G; Forand Y; Legrand A; Nachiket N; Dhenain M; Hermine O; Dubreuil P; Delarasse C; Delatour B
J Alzheimers Dis; 2020; 76(4):1339-1345. PubMed ID: 32623401
[TBL] [Abstract][Full Text] [Related]
8. Masitinib in treatment of pancreatic cancer.
Waheed A; Purvey S; Saif MW
Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
[TBL] [Abstract][Full Text] [Related]
9. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
10. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
[TBL] [Abstract][Full Text] [Related]
12. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
O' Neill C
Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
[TBL] [Abstract][Full Text] [Related]
13. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
Hamad AA; Amer BE; Hawas Y; Mabrouk MA; Meshref M
Neurol Sci; 2024 May; 45(5):1861-1873. PubMed ID: 38105307
[TBL] [Abstract][Full Text] [Related]
14. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
[TBL] [Abstract][Full Text] [Related]
15. Safety of masitinib mesylate in healthy cats.
Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
[TBL] [Abstract][Full Text] [Related]
16. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
[TBL] [Abstract][Full Text] [Related]
17. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
18. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
19. Fyn, a potential target for Alzheimer's disease.
Yang K; Belrose J; Trepanier CH; Lei G; Jackson MF; MacDonald JF
J Alzheimers Dis; 2011; 27(2):243-52. PubMed ID: 21799250
[TBL] [Abstract][Full Text] [Related]
20. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
Munoz L; Ammit AJ
Neuropharmacology; 2010 Mar; 58(3):561-8. PubMed ID: 19951717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]